News

Marksans Pharma Ltd share price gained 2.74% to Rs 278.9 after the company`s net profit saw a marginal increase of 6.97% to Rs 159.41 crore, while revenue from operations eased by 1.79% to Rs 840.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, easing 4.41%. It has marginally improved by 1.16% over last one week and moving up by 11.70% in last one month while the market capitalization of Marksans Pharma Ltd has improved by 3.11% and 38% in the same period respectively. Profit before tax (PBT) of Marksans Pharma Ltd stood at Rs 206.57 crore in Q2 FY26, rallying 169.67% year-on-year, and gaining 3.28% quarter-on-quarter. EBITDA came in at Rs 188 crore, surging by 98.59% YoY and expanding by 17.09% sequentially. Total expenses softened by 4.72% to Rs 652.63 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 220.67 crore, contracting by 16.72% YoY, while employee benefits expense was at Rs 114.29 crore, rising by 7.05% YoY. For the TTM ended FY26, revenue from operations improved 12.51% to Rs 2950.94 crore, while net profit saw a mild growth of 9.79% to Rs 420.06 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48060% to Rs 518.25 crore, and PBT registered a growth of 11.23% to Rs 560.56 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 458.13 crore in FY26, as against Rs 206.66 crore in FY25. Marksans Pharma Ltd rallied 32.97% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.04% during the same period.

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2026.

Marksans Pharma has completed the process of acquiring 100% share capital of ABCnow GmbH based in Germany.

Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. The company will acquire entire shareholding of ABCnow GmbH for a total consideration of � 892,384. The acquisition marks a strategic step in expanding Marksans` presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans` presence in the European markets.

Marksans Pharma announced that the 34th Annual General Meeting(AGM) of the company will be held on 27 August 2026.